Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma-Reference-Cited by-同舟云学术

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

Published:2014-03-26 Issue:7494 Volume:508 Page:118-122
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Sun Chong,Wang Liqin,Huang Sidong,Heynen Guus J. J. E.,Prahallad Anirudh,Robert Caroline,Haanen John,Blank Christian,Wesseling Jelle,Willems Stefan M.,Zecchin Davide,Hobor Sebastijan,Bajpe Prashanth K.,Lieftink Cor,Mateus Christina,Vagner Stephan,Grernrum Wipawadee,Hofland Ingrid,Schlicker Andreas,Wessels Lodewyk F. A.,Beijersbergen Roderick L.,Bardelli Alberto,Di Nicolantonio Federica,Eggermont Alexander M. M.,Bernards Rene

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature13121.pdf

Reference29 articles.

1. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011)

2. Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107–114 (2012)

3. Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100–103 (2012)

4. Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227–235 (2012)

5. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002)

Cited by 704 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review;Critical Reviews in Oncology/Hematology;2024-11

2. Targeted Therapy Innovations for Melanoma;Hematology/Oncology Clinics of North America;2024-10

3. Inverse correlation between TP53 gene status and PD-L1 protein levels in a melanoma cell model depends on an IRF1/SOX10 regulatory axis;Cellular & Molecular Biology Letters;2024-09-05

4. Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib);Cell Communication and Signaling;2024-08-23

5. The effects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis;Neurosurgical Review;2024-08-22